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Rapamycin, a specific inhibitor of the serine/threonine
mTOR kinase, markedly inhibited both cell growth and
apoptosis in human B-cell lines. Besides arresting cells in
G1 by increasing p27
kip1, rapamycin tripled the cellular
level of the BCL-2 protein. The activity was dose-
dependent and specific for the p27kip1 and BCL-2
proteins. Rapamycin did not aect bcl-2 mRNA although
it increased cellular BCL-2 concentration by inhibiting
phosphorylation, a mechanism initiating the decay
process. To add new insight, we combined rapamycin
treatment with treatment by taxol, which, by damaging
microtubules, can phosphorylate BCL-2 and activate
apoptosis. It was found that the mTOR kinase was
activated in cells treated with taxol or with nocodazole
although it was inhibited in cells pre-treated with
rapamycin. BCL-2 phosphorylation, apoptosis and
hyperdiploidy were also inhibited by rapamycin. In
contrast, taxol-induced microtubule stabilization or
metaphase synchronization were not inhibited by rapa-
mycin. Taken together, these findings indicate that
mTOR belongs to the enzymatic cascade that, starting
from damaged microtubules, phosphorylates BCL-2. By
regulating apoptosis, in addition to the control of a
multitude of growth-related pathways, mTOR plays a
nodal role in signaling G1 and G2-M events. Oncogene
(2001) 20, 6172 – 6180.
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Introduction
Besides human follicular B-cell lymphomas, in which the
bcl-2 gene was originally found (Tsujimoto et al., 1984;
Bakhshi et al., 1985; Cleary et al., 1986), bcl-2 over-
expression has been observed in a variety of human
tumors, thus providing the first indication of BCL-2
involvement in human cancer (Silvestrini et al., 1994;
Korsmeyer et al., 1990). Many other studies in
experimental systems (McDonnell et al., 1996) such as
bcl-2 transgenic (Strasser et al., 1990; Adams and Cory,
1991) or knock-out mice (Nakayama et al., 1993;
Korsmeyer, 1998; Veis et al., 1993) have directly related
BCL-2 antiapoptotic activity to neoplastic transforma-
tion and/or progression. BCL-2 protein has been shown
to lower cell sensitivity to chemotherapy and radio-
therapy (Reed et al., 1996; Kroemer, 1997). On the
contrary, reduced bcl-2 expression has been associated to
degenerative disorders including Parkinson’s disease or
Alzheimer’s disease (Saille et al., 1999).
Many attempts have been made to develop biologi-
cal or pharmacological means of modulating bcl-2
expression (Konig et al., 1997; Itano et al., 1996; Siegel
et al., 1998). Antisense compounds have shown
biological activity in switching o bcl-2 expression in
cell (Capaccioli et al., 1996; Morelli et al., 1996, 1997),
and are currently under clinical evaluation for anti-
lymphoma activity (Webb et al., 1997) and for
chemosensitization (Jansen et al., 2000). Both micro-
tubule-stabilizing agents such as taxol and microtubule-
damaging compounds such as nocodazole have been
shown to mediate phosphorylation of BCL-2 protein at
serine residues in the loop region (Srivastava et al.,
1999; Blagosklonny et al., 1996); phosphorylation
inactivates the antiapoptotic eect. Microtubule da-
mage induced by pharmacological means may trigger
apoptosis in cancer cells through a mechanism
involving BCL-2 phosphorylation (Haldar et al.,
1996). Moreover, arrest of cells in G2-M phase
consequent on damage to the mitotic apparatus may
be responsible for triggering a physiological mechanism
of cell demise. The biochemical pathways that link
microtubule damage with the BCL-2 phosphorylation-
inactivation leading the cells to activate apoptotic
programs, are not yet well known (Yamamoto et al.,
1999; Li et al., 1998).
Previously, in lymphoid cells, we observed that the
cell cycle arrest in G1 phase by rapamycin was
regulated by the amount of the BCL-2 protein
expressed at the steady state. These observations
prompted to study whether rapamycin might regulate
the BCL-2 pathway and apoptosis in cells treated with
taxol, a pro-apoptotic compound that damages micro-
tubules and down-regulates BCL-2.
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In mammalian cells, the immunophilin-binding
immunosuppressant rapamycin was shown to inhibit
mammalian target of rapamycin (mTOR/RAFT-1/
FRAP), a serine/threonine kinase whose function is
not entirely understood (Sehgal, 1998). In yeast,
rapamycin-mediated inhibition of TOR1 and TOR2,
two kinases homologous to human mTOR, induces a
starvation-like response (Schmidt et al., 1998) and can
hinder the cell cycle-dependent organization of the
cytoskeleton (Bickle et al., 1998). In human, mTOR is
mainly implicated in the signaling of cell growth and
proliferation from growth factors and amino acids
abundance (Hara et al., 1998; Nave et al., 1999). More
recently, mTOR has been shown to control an
unusually abundant and diverse set of readouts,
eliciting to the spatial and temporal control of
balanced cell growth (Schmelzle and Hall, 2000; Choi
et al., 2000).
In this study human follicular B-cell lymphoma lines
endowed with high levels of BCL-2 at steady state were
exposed to rapamycin. We found that rapamycin was
able to increase cellular levels of BCL-2 protein in
addition to p27kip1 protein. Prior treatment of cells with
rapamycin inhibited taxol-induced apoptosis and DNA
endoreduplication (Stewart et al., 1999), while having
no eect on microtubule stabilization and on arrest in
the G2-M phase. Prediction was made that the mTOR
kinase was activated by antimicrotubules agents and
might be included in the kinase cascade whereby the
apoptosis triggered by microtubule damage is brought
about.
Result
Rapamycin induces the selective accumulation of BCL-2
and p27kip1 proteins
In a program to study the molecular mechanisms
regulating bcl-2 expression, we found that rapamycin
inhibited the cell growth of follicular lymphoma cell
lines very eciently. In three human follicular t(14;
18)-positive cell lines, cells were arrested in the G1
phase of the cell cycle at doses not eective in t(14; 18)-
negative cell lines (Table 1). The activity of rapamycin
was dose-dependent and at 1 ng/mL the percentage of
G1 fraction was 36% higher than in the untreated
control. Moreover, rapamycin did not increase the
hypodiploid cell fraction and in preliminary studies
apoptosis induced by pharmacological means was
reduced.
These findings and those of others (Kitamura et al.,
1997; Migita et al., 1997) prompted us to measure the
cellular levels of BCL-2 protein and of the relevant
mRNA. These last were not modified upon exposure to
rapamycin (not shown), whilst those of the BCL-2
protein increased up to threefold upon the same
treatment. As expected, the cellular level of the p27kip1
protein underwent the same fate (Figure 1a). In the
same assays, the concentrations of the apoptosis-
related protein BCL-XL or BAX and of the cell-cycle
regulators p21, CDK 2 and Cyclin E were not
augmented. The increases of BCL-2 and p27kip1
proteins were dependent on the rapamycin concentra-
tion. The levels reached a peak after 24 h and were still
high after 48 h (Figure 1b).
These findings indicated that a post-transcriptional
mechanism could underlie the rapamycin-mediated
BCL-2 increase as it does with p27kip1 (Vlach et al.,
1997).
Rapamycin inhibits taxol-induced BCL-2
phosphorylation, DNA endoreduplication and apoptosis
The rapamycin-mediated inactivation of the kinase
cascade starting from mTOR might account for the
rapamycin-mediated inhibition of BCL-2 phosphoryla-
tion. By contrast, taxol treatment can phosphorylate
BCL-2 causing functional inactivation. Cells were
incubated 24 h with rapamycin and then treated with
taxol for further 24 h. As shown in Figure 2,
rapamycin prevented taxol-induced BCL-2 phosphor-
ylation in a dose-dependent fashion. In these studies
taxol has been used within the clinical relevant doses
Table 1 Growth rate and cell cycle analysis of lymphoma cells treated with rapamycin
Cell treatments Growth rate Cell cycle
Cell line Rapamycin (ng/mL) Cell number6103+s.e.m. MTT assay OD6s.e.m. Hypo G1 S G2/M
DOHH2 – 424+33 1250+78 8 38 32 22
3 132**+27 483**+50 9 59** 17 15
1 196**+21 539**+42 9 49** 25 17
0.3 217**+29 667**+61 8 44* 27 21
SU-DHL 4 – 640+50 1416+69 7 36 36 21
3 169**+21 450**+36 7 52** 22 19
1 268**+33 610**+51 7 48** 24 21
0.3 380*+37 825**+59 5 40* 35 20
K-422 – 563+49 1322+75 10 31 33 26
3 258**+15 611**+63 10 48** 17 25
1 373*+36 803**+86 10 45** 20 25
0.3 437*+41 989*+91 8 37* 32 23
Rapamycin was given as a single dose at the indicated concentrations on day 0. On day 3, cultures were arrested and cells were counted under
the microscope and analysed by the MTT assay. Assays were performed in triplicate and data are representative of 4 – 6 experiments. Cell cycle
was studied in cells incubated for 24 h in the presence of 3, 1 or 0.3 ng/mL of rapamycin, respectively. The percentage distribution over the cell
cycle was measured by flow cytometry. **P40.005, *P40.05
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(5 – 200 nM) (Blagosklonny and Fojo, 1999) or at
higher doses to understand the magnitude of inhibition
of phosphorylation by a low dose of rapamycin.
The biochemical mechanisms underlying taxol activ-
ity were studied in some detail in the rapamycin-
pretreated cells, with more emphasis in the BCL-2
overexpressing lymphoma B-cell lines. At the end of
the pharmacological treatments, genomic DNA was
stained with propidium iodide and analysed by flow
cytometry. Figure 3 shows that combined treatment
with rapamycin and taxol caused the arrest in G2-M
phase of a higher number of cells (70% of total cells)
than taxol alone (50% of cycling cells). Taxol was
probably more eective than rapamycin in arresting
cell cycle causing G1 arrested cells by rapamycin to
accumulate into the more definitely G2-M phase arrest.
A second observation was that rapamycin totally
inhibited the ability of taxol to induce mitotic slippage
shown as 44N in Figures 3 and 4. Thus, taxol did not
relieve the inhibition of DNA synthesis by rapamycin,
which entirely blocked endoreduplication. Cytometry
analysis also showed that rapamycin protected cells
from taxol-induced apoptosis.
The DNA distribution in rapamycin pre-treated cells
exposed to increasing doses of taxol was extensively
studied in lymphoma lines including three t(14; 18)
lymphoma lines. Rapamycin was confirmed to inhibit
with high eciency the biological eects of taxol as
studied by flow cytometry. In particular, apoptosis was
reduced significantly and hyperploidy completely, in
spite of the heavy alteration produced by a high dose
of taxol as shown in Figure 4.
Taxol-mediated microtubule stabilization is not impaired
in cells pretreated with rapamycin
Since the main biochemical eect of taxol is to stabilize
the microtubule apparatus, which activates the apoptotic
program, we studied the eect of taxol on microtubule
stabilization in rapamycin-pretreated cells. Figure 5a
was obtained by staining microtubules with fluorescent
a-tubulin antibodies and shows that the stabilization of
microtubules by 2 h exposure of cells to taxol was not
impaired by prior treatment with rapamycin. Figure 5b
shows that the accumulation of cells treated with taxol in
the prometaphase is not significantly inhibited by a pre-
treatment with rapamycin.
Taxol or nocodazole activate the serine/threonine mTOR
kinase
Because taxol phosphorylates BCL-2 protein and
rapamycin inhibits this phosphorylation by acting on
mTOR, we investigated whether taxol might induce the
activation of mTOR. Taxol indeed induced the
Figure 1 Increased expression of BCL-2 and p27kip1 proteins in
lymphoma line treated with rapamycin. (a) DOHH2 cells were
treated for 24 h with rapamycin at the indicated doses. Cell
extracts, 25 mg of proteins or 12 mg for BCL-2 determination,
were separated by SDS–PAGE, Western blotted and analysed for
the expression of the relevant proteins as indicated. All blots were
probed for b-actin and assays were repeated three times. (b)
DOHH2 cells, treated with 30 or 10 ng/mL rapamycin, were
analysed for BCL-2 protein expression by Western blot for the
indicated periods
Figure 2 Inhibition of taxol-induced BCL-2 phosphorylation by
rapamycin. DOHH2 cell line (a) or K422 cell line (b) treated with
rapamycin, 10 ng/mL at time 0, on day 1 were untreated or
treated with taxol at the indicated doses for a further 24 h. Cell
extracts were analysed in Western blot with an anti-BCL-2
MoAb. The hypophosphorylated form of BCL-2, not reduced by
taxol, lanes 2 – 4 versus lane 1, was reduced in rapamycin pre-
treated cells, lanes 5 – 7 versus lane 8
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phosphorylating activity of mTOR (Figure 6, upper
panel) without aecting its steady-state level in cells, as
shown in Figure 6 (lower panel). Extracts from K422
cells, treated 24 h with dierent doses of taxol, were
immunoprecipitated with both mTab1 and mTab2
rabbit antibodies and resuspended in the kinase buer
containing recombinant PHAS-I or recombinant BCL-
2. mTOR immunoprecipitates from cells treated with
300 or 30 nM of taxol were able to phosphorylate
PHAS-I, while 3 nM was almost ineective. However, a
direct activity of mTOR on BCL-2 might be excluded
since recombinant BCL-2 in the kinase buer was not
phosphorylated by activated mTOR (not shown).
Figures 7 and 8 show that mTOR activity triggered
by taxol or nocodazole, respectively, was significantly
reduced in the immunoprecipitated samples from cells
pre-treated with rapamycin. The Western blot determi-
nation of mTOR in the immunoprecipitates ruled out
the possibility that reduced activity might be dependent
on the failure of antibody to immunoprecipitate the
rapamycin-FKBP12-mTOR complex.
Therefore, mTOR, the molecular target for the
biological eects of rapamycin, recently strengthened
by studies in cells carrying mTOR resistant to
rapamycin, strongly associate it to the kinase cascade
that phosphorylates BCL-2 in mitotic arrested cells
(Brunn et al., 1997).
Discussion
Very important pathways of cell life such as protein
synthesis, cell proliferation and apoptosis are often
controlled in a coordinated fashion (Lundberg and
Weinberg, 1999; Guo and Bruce, 1999) by growth
factors. Rapamycin, by inhibiting protein synthesis
(Crossin and Carney, 1981; Terada et al., 1995) and
arresting the cell-cycle in G1 (Hashemolhosseini et al.,
1998; Metcalfe et al., 1997) is able to induce a ‘growth-
factor withdrawal’ condition (Schmidt et al., 1998).
Whether starvation conditions induced by rapamycin
can play some role in the regulation of the apoptotic
programs activated by pharmacological means is not
yet well known (Abraham, 1998).
Rapamycin activates an anti-apoptotic program
The biochemical events triggered by rapamycin were
studied in three human follicular B-cell lymphoma
lines that contain a high concentration of BCL-2
protein (Aiello et al., 1992; Steube et al., 1995) and
are most sensitive to rapamycin. The lowest doses of
rapamycin inhibited growth and arrested the cell lines
in the G1 phase. In these studies it was also noticed
that cell cultures were protected from spontaneous
apoptosis and from apoptosis induced by treatments
with taxol. Inactivation of the apoptotic program
prompted our studies on the expression of the bcl-2
gene in cells exposed to rapamycin. We observed that
the cellular concentration of the bcl-2 mRNA was
unchanged, whereas that of BCL-2 protein was
significantly increased in a dose-dependent fashion
and correlated with the increased level of p27kip1
protein (Ko and Polyak, 1995; Alessandrini et al.,
1997; Cordon-Cardo et al., 1998). The increased level
of the proteins by rapamycin was specific for BCL-2
and p27kip1, since the cell concentrations of neither the
apoptosis-related proteins BCL-XL and BAX nor the
cell-cycle regulators p21, CDK-2 and cyclin-E were
changed. This observation suggested that BCL-2 and
Figure 3 DNA distribution in rapamycin pre-treated cells exposed to taxol treatments. DOHH2 cells, treated with rapamycin,
10 ng/mL at time 0, on day 1 were untreated or treated with taxol at 300, 30 or 3 nM for a further 24 h. Cells, stained with
propidium iodide, were analysed by flow cytometry. Upper rows, no rapamycin (7); lower rows, rapamycin 10 ng/mL (R). In the
top-right of the histograms are indicated the percentage of hypodiploid cells (Hypo) or hyperdiploid cells (44N), respectively.
Histograms are representative of 4 – 5 experiments
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p27kip1 could be modulated by common pathways or a
coordinated mechanism. Such biochemical modifica-
tions are associated with the activation of an anti-
apoptotic program and with the arrest of cells in the
G1 phase.
Damaged microtubules activate the mTOR kinase
Taxol can induce BCL-2 phosphorylation at position
serine (Srivastava et al., 1999; Haldar et al., 1997)
causing the inactivation of BCL-2 (Chadebech et al.,
1999) and consequent loss of anti-apoptotic function.
BCL-2 phosphorylation and the pro-apoptotic pro-
gram triggered by taxol in the lymphoma cells were
greatly inhibited by prior treatment with rapamycin in
a dose-response manner. Moreover, prior treatment
with rapamycin completely inhibited the taxol-induced
hyperdiploidy but did not prevent taxol-induced
microtubule damage.
The inhibition of BCL-2 phosphorylation despite
microtubule alteration, prompted us to study the
biochemical signaling activated by microtubules. Our
attention has been focused on the threonine/serine
mTOR kinase. The immunoprecipitation studies pro-
vided evidence that treatment with taxol or nocodazole
activated mTOR which indicated an important role in
the kinase cascade regulating BCL-2 phosphorylation
and loss of function.
In the first part of the work we show that
rapamycin is able to increase the cellular level of the
BCL-2 protein and protect lymphoma cells from
apoptosis. The increase of BCL-2 protein is achieved
by inhibition of BCL-2 phosphorylation and might be
more evident in cells containing a large amount of
Figure 4 DNA distribution in rapamycin pre-treated t(14; 18) cells exposed to taxol at high dose. SU-DHL-4, DOHH2 and K422
cell lines, were untreated (7), treated with rapamycin, 48 h at 10 ng/mL (R), treated with taxol, 24 h at 300 nM (T), or pre-treated
with rapamycin, 24 h at 10 ng/mL, and with taxol for a further 24 h at 300 nM (R+T). Cells were processed as in Figure 3 and
histograms are representative of three experiments
mTOR regulates apoptosis and cell cycle
A Calastretti et al
6176
Oncogene
BCL-2 in the steady state. We show here that agents
that damage microtubules can induce BCL-2 phos-
phorylation-inactivation through a pathway that
involves the mTOR kinase. This pathway might be a
physiological mechanism for the elimination of cancer
cells with damaged mitotic apparatus (Haldar et al.,
1997). In contrast, impaired mTOR activity, such as
that mediated by rapamycin, might hinder the
elimination of damaged cells inducing resistance to
anticancer therapy or protecting tissues from degen-
eration.
In this scenario, the role of p27kip1 remains to be
elucidated. Taxol has never been directly demon-
strated to inactivate p27kip1 by phosphorylation. The
concept of p27kip1 inactivation might not be in contrast
with the observation of hyperdiploidy in cells
hampered to divide because of damage of mitotic
apparatus. However, the possibility that taxol does
not enter in the regulation of p27kip1 already
inactivated by signals from the growth factors cannot
be ruled out.
In conclusion, damaged microtubules can induce an
apoptotic program by activating a biochemical
cascade that includes serine/threonine kinases and
mTOR. The findings discussed here might indicate a
key role for the mTOR kinase in relevant metabolic
steps of the G2-M phase in addition to the role of
central controller of cell growth. A coordinate
regulation of cell cycle and apoptosis by means of
mTOR might be envisaged.
Material and methods
Cell lines and drugs
The human follicular B-cell lymphoma lines DOHH2 (Kluin-
Nelemans et al., 1991), SU-DHL-4 (Cleary et al., 1986) and
K422 (Dyer et al., 1990), carrying the t(14; 18) chromosomal
translocation, all mycoplasma-free, were grown in RPMI
a
b
Figure 5 (a) Microtubule stabilization by taxol in cells pre-
viously treated with rapamycin. DOHH2 cells were: untreated (a),
treated with rapamycin, 22 h at 10 ng/mL (b), untreated 22 h and
treated with taxol, 2 h at 200 nM (c), treated with rapamycin, 22 h
at 10 ng/mL and with taxol 2 h at 200 nM. Cells were stained with
fluoresceinated anti-tubulin monoclonal antibody and photo-
graphed at 636magnification. (b) Mitotic Index. DOHH2 cells,
treated with rapamycin, 10 ng/mL at time 0, on day 1 were
untreated or treated with taxol at 300, 30 or 3 nM for a further
24 h, and then stained with eosine-hematoxylin. The mitotic index
was determined by scoring 1500 cells on each sample. Values are
expressed as the percentage of the mitotic index of control cells.
Samples were run in triplicate and data represent mean values
from three independent experiments
Figure 6 mTOR protein kinase activity from cells treated with taxol. K422 cells, treated with taxol, 24 h at 300, 30 or 3 nM, were
lysed and extracts, quantitated by Western blottings (lower panel), were immunoprecipitated either with mTAb1 or with mTAb2
rabbit antibodies, respectively. The substrate for the kinase reactions was the human recombinant PHAS-I. The products were
separated by SDS–PAGE and detected by autoradiography. Data are representative of three assays
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1640 medium (Mascia Brunelli, Milan, Italy) containing
10% heat-inactivated FCS (HyClone Laboratories, UT,
USA), 2 mM glutamine, 50 IU/mL penicillin and 50 mg/ml
streptomycin (Sigma-Aldrich, Milan, Italy) at 378C in a 5%
CO2 atmosphere. The nucleotide sequence of the bcl-2/IgH
joining region of the t(14; 18)-positive cells were frequently
checked. Rapamycin, kindly supplied by Dr Sehgal (Wyeth-
Ayerst Research, NJ USA), was dissolved in absolute
ethanol to generate a 2 mM solution and small aliquots of
the stock solution were stored at 7808C. Taxol and
Nocodazole (Sigma-Aldrich) were dissolved in DMSO to
generate a 1 mM solution or 10 mM solution, respectively
and small aliquots of the stock solutions were stored at
7208C.
Growth rate assay
Cultures, 25 – 1006103 cells/mL in 24-well plates (Greiner),
split twice weekly to avoid crowding, were washed,
resuspended in RPMI 1640 medium (Mascia Brunelli)
containing 10% FCS and the same glutamine and antibiotic
concentrations as above and exposed to rapamycin as
indicated. Growth rate and viability of the cells were
determined by the Trypan blue exclusion assay and by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT)-based colorimetric assay (Mosmann, 1983).
Western blot analysis of the proteins
Samples of 46106 cells, treated with rapamycin as indicated,
were collected by low-speed centrifugation and washed twice
in ice-cold PBS plus 1 mM sodium orthovanadate. The cell
pellet was resuspended in 60 mL of lysis buer (ice-cold RIPA
buer with freshly added protease inhibitors), vortexed for
3 s and incubated on ice for 30 min. The lysates were
centrifuged at high speed for 20 min at 48C. Five mL of the
supernatant was removed for protein determination, trans-
ferred to a microfuge tube, mixed with reducing buer and
heated to 998C for 2 min. Equal amounts of proteins, unless
specified, were analysed by 12% SDS–PAGE, blotted onto
PVDF membranes (Immobilon P, Millipore, Bedford, MA,
USA) in a Bio-Rad Trans-blot apparatus at 100 V for
90 min. Blots were processed by an enhanced chemilumines-
cence (ECL Plus) detection kit as instructed by the supplier
(Amersham Pharmacia Biotech, UK). The blots were probed
with a mouse anti-BCL-2 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), followed by a horseradish peroxidase,
conjugated secondary antibody. The same blots were then
Figure 7 mTOR protein kinase activity from cells pre-treated with rapamycin and treated with taxol. K422 cells, treated with
rapamycin, 10 ng/mL at time 0, on day 1 were untreated or exposed to taxol for a further 24 h at the doses indicated. Cell extracts
were obtained and processed as described in Figure 6. Data are representative of three assays
Figure 8 mTOR protein kinase activity from cells pre-treated with rapamycin and treated with nocodazole. DOHH2 cells, treated
with rapamycin, 10 ng/mL at time 0, on day 1 were untreated or exposed to 1, 0.3, 0.1 mM nocodazole for a further 24 h at the
doses indicated. Cell extracts were obtained and processed as described in Figure 6. Data are representative of three assays
mTOR regulates apoptosis and cell cycle
A Calastretti et al
6178
Oncogene
probed for p27kip1 and BAX (DAKO, Milan, Italy), p21
(NeoMarkers, Freemont, CA, USA), BCL-XL (Pharmingen,
San Diego, CA, USA), CDK2 and Cyclin E (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and for b-actin
(Sigma-Aldrich) using appropriate antibodies.
Western blot analysis for the phosphorylated form of BCL-2
protein
Samples of 86106 cells, treated with rapamycin and taxol as
indicated, were collected and resuspended in 320 mL of
Laemmli buer (Laemmli, 1970), boiled for 2 min, protease
inhibitors were added and the mixture was sonicated for 20 s.
Supernatants containing protein extracts were collected and a
1 : 10 volume of BMG (glycerol:b-mercaptoethanol: bromo-
phenol-blue, 1%/2 : 5 : 5) was added; they were then boiled for
3 min and stored at 7208C. Protein concentration was
determined using the Micro BCA Protein Assay Reagent
(Pierce, Rockford, IL, USA). Aliquots of 130 mg were size-
separated by SDS –PAGE (12%, 1.5 mm thick gel 70.8%
Bis-acrylamide/30% acrylamide) at 80 V overnight and
blotted onto a PVDF membranes (Immobilon P) in a BIO-
RAD Trans-Blot semi-dry apparatus at 15 V for 60 min.
Immunodetection was carried out using an anti-BCL-2
(DAKO, Milan, Italy) monoclonal antibody (1 : 100), and
blots were successively developed with peroxidase anti-mouse
antibody (1 : 2000), using the enhanced chemiluminescence kit
(Pratesi et al., 2000).
Analysis of cellular DNA content by flow cytometry
Cells treated as indicated were collected and washed in PBS
for 10 min at 1500 r.p.m., then permeabilized with 200 mL of
PBS containing 0.1% Saponin and 0.5 mg/mL RNAse (type
IIIA, Sigma-Aldrich) for 30 – 40 min at 378C. Eight hundred
mL of DNA-staining solution, 0.1% saponin and propidium
iodide (25 mg/mL in PBS), were added for 30 min at 48C
(Nicoletti et al., 1991). The cellular DNA content was
analysed by flow cytometry with a FACscan (Becton
Dickinson, CA, USA). Histograms of cell frequency vs
propidium iodide fluorescence intensity, which is proportional
to DNA content, were analysed using the Lysis II software
system (Becton Dickinson).
Microtubule staining and Mitotic Index
The distribution of a-tubulin was analysed by the indirect
immunofluorescence technique (Schi and Horwitz, 1980).
The cells, treated as indicated, were fixed and permeabilized
for 5 min with methanol at 7208C, washed with PBS 1X and
incubated with monoclonal anti-a-tubulin conjugated with
FITC (1 : 75 in PBS+0.05% Triton X) (Sigma-Aldrich), in a
humid atmosphere for 90 min at 378C and in the dark. After
two washes with PBS and with water, respectively, the
preparations were mounted with 70% glycerol, 10% PBS and
1 mg/mL p-phenylenediamine (Sigma-Aldrich). The cover-
slips were viewed with a Zeiss Axioskop (Germany)
microscope equipped with epifluorescent optics. Pictures were
taken with an oil-immersion objective (636) on Ektachrome
400 Kodak film.
DOHH2 cells, treated with rapamycin, 10 ng/mL at time 0,
on day 1 were untreated or treated with taxol at 300, 30 or
3 nM for a further 24 h and then collected, washed twice in
PBS for 10 min at 1500 r.p.m. and stained with eosine-
hematoxylin. The mitotic index was determined by scoring at
least 1500 cells on each sample.
mTOR activity
mTOR was immunopurified as described in Brunn et al.
(1997) with minor modifications. Briefly, K422 cells, treated
with taxol, were washed in cold PBS and lysed at 48C in a
solution containing 50 mM Tris/HCL, 150 mM NaCl, 2 mM
EDTA, 2 mM EGTA, 25 mM NaF, 25 mM b-glycerolpho-
sphate, 0.1 mM Na3VO4, 0.1 mM PMSF, 5 mg/mL leupeptin,
1 mg/mL aprotinin, 0.2% Triton X-100, 0.3% Nonidet P-40.
Lysates, clarified by centrifugation at 13 000 r.p.m. for
25 min at 48C, were immunoprecipitated by the rabbit
antibodies mTAb1 or mTAb2 (kindly provided by Dr JC
Lawrence) (Brunn et al., 1997). The immune complexes were
suspended in 50 mL of kinase buer containing 10 mM
MgCl2, 20 mM Tris/HCl pH 7.4, 1 mM DTT, 30 mM ATP,
1 mg [His6]-PHAS-I (Stratagene, CA, USA), 5 mCi of
[g-32P]ATP and analysed by SDS–PAGE electrophoresis.
Radiolabeled PHAS-I was detected by autoradiography.
Incorporation of 32P into PHAS-I was quantified with an
Ambis Imaging system.
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